First Oral Drug for Moderate-To-Severe Ulcerative Colitis

被引：0
|
作者：
Aschenbrenner, Diane S.
机构：
来源：
AMERICAN JOURNAL OF NURSING | 2018年 / 118卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
Immediate-release tofacitinib (Xeljanz) is now approved to treat moderate-to-severe ulcerative colitis. Nurses should assess patients for infections prior to the initiation of and throughout tofacitinib treatment.
引用
收藏
页码：22 / 22
页数：1
相关论文
共 50 条
  • [21] Responsiveness of different disease activity indices in moderate-to-severe ulcerative colitis
    Solitano, Virginia
    Panaccione, Remo
    Sands, Bruce E.
    Wang, Zhongya
    Hogan, Malcolm
    Zou, Guangyong
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    Cornfield, Linda J.
    Feagan, Brian G.
    Singh, Siddharth
    Jairath, Vipul
    Ma, Christopher
    MED, 2025, 6 (02):
  • [22] Therapeutic options for children and young people with moderate-to-severe ulcerative colitis
    Ashton, James
    Lee, Kwang Yang
    Thangarajah, Anthi
    Rodrigues, Astor
    Kammermeier, Jochen
    FRONTLINE GASTROENTEROLOGY, 2024, 15 (05) : 387 - 394
  • [23] Positioning ustekinumab in moderate-to-severe ulcerative colitis: new kid on the block
    Fiorino, Gionata
    Allocca, Mariangela
    Correale, Carmen
    Roda, Giulia
    Furfaro, Federica
    Loy, Laura
    Zilli, Alessandra
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (04) : 421 - 427
  • [24] Cytomegalovirus colitis in patients with moderate-to-severe Ulcerative Colitis: diagnosis, clinical impact and treatment efficacy
    Melotti, L.
    Salice, M.
    Rinaldi, M.
    Dussias, N.
    Vanigli, N.
    Scaioli, E.
    Hrustemovic, H. Privitera
    Rizzello, F.
    Gionchetti, P.
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : I567 - I568
  • [25] COST-EFFECTIVENESS OF VEDOLIZUMAB FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS IN THAILAND
    Sruamsiri, R.
    VALUE IN HEALTH, 2018, 21 : S2 - S2
  • [26] Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
    Warner, Ben
    Harris, Adam W.
    GASTROENTEROLOGY, 2012, 143 (01) : E42 - E42
  • [27] Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis
    Wu, Bin
    Wang, Zhenhua
    Zhang, Qiang
    INFLAMMATORY BOWEL DISEASES, 2018, 24 (11) : 2291 - 2302
  • [28] Addition of leukocytapheresis to steroid therapy - Is it beneficial in recurrence of moderate-to-severe ulcerative colitis?
    Jo, Y
    Matsumoto, T
    Mibu, R
    Iida, M
    DISEASES OF THE COLON & RECTUM, 2003, 46 (10) : S3 - S9
  • [29] Economic evaluation of vedolizumab SC for the treatment of moderate-to-severe ulcerative colitis in Canada
    Fischer, A.
    Oppe, M.
    Stypa, S.
    Lukyanov, V.
    Petrakis, I.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S387 - S387
  • [30] Induction and maintenance of clinical remission by adalimumab in patients with moderate-to-severe Ulcerative Colitis
    Sandborn, William
    Van Assche, Gert
    Reinisch, Walter
    Colombel, Jean-Frederic
    D'Haens, Geert
    Wolf, Douglas
    Kron, Martina
    Tighe, Mary
    Lazar, Andreas
    Thakkar, Roopal
    INFLAMMATORY BOWEL DISEASES, 2011, 17 : S3 - S4
12345